Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Late-Stage Pipeline Reflects Success Of In-House Development

Executive Summary

Bristol-Myers Squibb's late-stage pipeline will include 80% internally developed agents, with three of those compounds moving into Phase III

You may also be interested in...



Bristol R&D Success Shows Link Between Licensing And First-Cycle Approval

Bristol-Myers Squibb's heavy reliance on in-licensing products in the first half of the decade appears to have paid off with a high number of new molecular entity submissions and a relatively strong first-cycle approval record

Bristol R&D Success Shows Link Between Licensing And First-Cycle Approval

Bristol-Myers Squibb's heavy reliance on in-licensing products in the first half of the decade appears to have paid off with a high number of new molecular entity submissions and a relatively strong first-cycle approval record

Bristol Baraclude Will Be Available April 8; Premium Price Planned

Bristol-Myers Squibb's Baraclude (entecavir) will be available on pharmacy shelves April 8 following FDA approval of the hepatitis B therapy

Related Content

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel